FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: *Pivot Pharmaceuticals Inc. (the “Issuer”)*

Trading Symbol: *PVOT*

Number of Outstanding Listed Securities: *171,039,468 common shares*

Date: *July 8, 2019*

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*In June 2019, Pivot continued to work with its distribution partners in the European Union countries, where regulations permit, to secure purchase orders for the initial production of micellized CBD solution with SomMic GmbH.*

*Pivot also continued to strengthen its management team as it commences commercial production and sales. In June 2019, Pivot added Dr. Ken Kessler to its Board of Directors, joining Dr. Wolfgang Renz, Dr. Joseph Borovsky and Mr. Krisztian Toth. Dr. Patrick Frankham stepped down as director and remains as Pivot’s Chief Executive Officer. Also in June 2019, Pivot appointed Mr. Chris Lucky as its Chief Operating Officer.*

*Pivot’s fully owned subsidiary, Pivot Naturals, LLC, obtained its provisional Adult-Use and Medicinal Distributor-Transport Only License, which is effective from June 4, 2019 to June 3, 2020. This is in addition to the provisional Annual Manufacturing License for Adult and Medicinal Cannabis Products (Type N: Infusion) effective from May 20, 2019 to May 20, 2020.*

1. Provide a general overview and discussion of the activities of management.

*Please see Item 1.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*N/A.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*N/A.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*N/A.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*N/A.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*N/A.*

1. Describe the acquisition of new customers or loss of customers.

*N/A.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*During June 2019, Pivot re-filed three provisional patents applications that had expired, including a) cannabis transdermal delivery application; b) cannabis mucosal delivery application and c) cannabis delivery application via inhalation process. These provisional applications will be converted to a patent applications with additional testing results to be completed.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*Please see Item 1.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*N/A.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*N/A.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*During June 2019, Pivot repaid its promissory note and accrued interest totalling $307,159.*

1. Provide details of any securities issued and options or warrants granted.

*During June 2019, Pivot cancelled 700,000 options for the purchase of common shares. On June 12, 2019, Pivot granted 2,700,000 options for the purchase of 2,700,000 common shares with an exercise price of $0.40 and expiry date of June 11, 2024.*

1. Provide details of any loans to or by Related Persons.

*N/A.*

1. Provide details of any changes in directors, officers or committee members.

*Please see Item 1.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*The Swiss government collected $15 million of taxes from legal sales of cannabis in 2018, pointing to a significantly increase in demand of cannabis. Potential further growth of demand in Switzerland is significant given Switzerland is one of the most affluent countries in the world.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 8, 2019

 Moira Ong
Name of Director or Senior Officer

 *“Moira Ong”*
Signature

Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerPivot Pharmaceuticals Inc. | For Month EndJune 2019 | Date of ReportYY/MM/DD2019/07/08 |
| Issuer Address1275 West 6th Avenue, Suite 300 |
| City/Province/Postal CodeVancouver, BC V6H 1A5 | Issuer Fax No.( ) | Issuer Telephone No.( ) |
| Contact NameMoira Ong | Contact PositionCFO | Contact Telephone No.604-551-5178 |
| Contact Email Addressinfo@pivotpharma.com | Web Site Addresswww.pivotpharma.com |